CD19 CAR-T mechanisms of action and resistance

ESH eLearning, Marco Ruella, 374683

Panel Discussion

ESH eLearning, Faculty / Presenters, 374682

Selected brief oral communication: Subcutaneous epcoritamab combined with R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma: phase 1/2 update

ESH eLearning, Michael Roost Clausen, 374681

Case-based lecture: Is auto-transplant over in diffuse large B-cell lymphoma?

ESH eLearning, Marek Trneny, 374680

Case-based lecture: Relapsed (not autologous stem cell transplant /CAR T eligible)

ESH eLearning, Armando Lopez-Guillermo, 374679

Case-based lecture: Front line therapy (focus on high risk)

ESH eLearning, Kim Linton, 374678

Case-based lecture: Consolidation radiation therapy in diffuse large B-cell lymphoma?

ESH eLearning, Viola Pöschel, 374677

Discussion

ESH eLearning, Faculty / Presenters, 374676

Autologous and allogeneic stem cell transplant for T-cell lymphoma

ESH eLearning, Silvia Montoto, 374674

Final vote

ESH eLearning, Faculty / Presenters, 374673

Con

ESH eLearning, Alison Moskowitz, 374672

Pro

ESH eLearning, Peter Borchmann, 374671

Introduction

ESH eLearning, Graham Collins, 374670

Panel Discussion

ESH eLearning, Faculty / Presenters, 374709

Selected brief oral communication: Subcutaneous epcoritamab combined with rituximab + lenalidomide for the treatment of patients with relapsed or refractory follicular lymphoma: phase 1/2 trial update

ESH eLearning, Lorenzo Falchi, 374669

Case-based lecture: Relapsed follicular lymphoma: which cellular therapy: Auto, Allo or CAR T, Bispecific

ESH eLearning, Caron Jacobson, 374668

Case-based lecture: Optimal front line approach for high-risk follicular lymphoma

ESH eLearning, Stefano Luminari, 374667

Case-based lecture: Understanding biology of high risk follicular lymphoma - EZH, a new target for follicular lymphoma?

ESH eLearning, Kai Hübel, 374666

Interactive case: Recognizing high risk

ESH eLearning, Jessica Okosun, 374665

Panel Discussion

ESH eLearning, Faculty / Presenters, 374664

Case-based lecture: Salvage therapy in peripheral T-cell lymphoma

ESH eLearning, Alison Moskowitz, 374663

Case-based lecture: Front-line 'personalized' therapy of common PTCL subtypes

ESH eLearning, Alison Moskowitz, 374662

Panel Discussion

ESH eLearning, Faculty / Presenters, 374660

Selected brief oral communication: Clinicopathological features and outcome of CD5 positive diffuse large B cell lymphoma and significance of CD5 expression strength: 10-year single center experience

ESH eLearning, Vojin Vukovic, 374659

Case-based lecture: Advanced - how to choose optimal therapy in the context of refining the risk assessment (TMT, Ctdna)

ESH eLearning, Anca Prica, 374657

Case-based lecture: Limited stage Hodgkin lymphoma

ESH eLearning, Marc Andre, 374656

Interactive case : Elderly patients with Hodgkin lymphoma: chemo or not chemo?

ESH eLearning, Graham Collins, 374655

Welcome address

ESH eLearning, Faculty / Presenters, 374654

Conference Book (PDF)

ESH eLearning, Faculty / Presenters, 374705

Selected abstract:Immunological response to sars-cov-2 after infection and/or vaccination among CML patients – a prospective study

ESH eLearning, Jorge Cortes, 374418

Selected abstract:Adverse impact of HMGCLL1 gene variant on treatment outcomes including response, failure and progression with imatinib can be abrogated by the use of 2nd generation tyrosine kinase inhibitor therapy in chronic myeloid leukemia

ESH eLearning, Dennis Kim, 374417

Selected abstract:Treatment and long-term follow-up of children with CML in chronic phase in the TKI Era: more than 2 decades of experience from the Tata Memorial Hospital paediatric CML cohort

ESH eLearning, Nirmalya ROY MOULIK, 374416

Patients perspective on cure in CML

ESH eLearning, Giora Sharf, 374415

20 years of evidence-based patient advocacy in CML: a story of close collaboration with researchers

ESH eLearning, Jan Geissler, 374414

Selected abstract: UK real world of experience of asciminib

ESH eLearning, Andrew Innes, 374410

Selected abstract:Clinical outcome of asciminib treatment in a real-world multi-resistant CML patient population

ESH eLearning, Camille C.B. Kockerols, 374409

Phase separation-based mechanisms underlying 3D chromatin structure reorganization and CML blast crisis

ESH eLearning, Greg Wang, 374401

Keynote Presentation:Clinical trials and the real world: how do they correlate

ESH eLearning, Dragana Milojkovic, 374408

Discussion

ESH eLearning, Faculty / Presenters, 374406

Asciminib

ESH eLearning, Delphine Rea, 374405

Ponatinib

ESH eLearning, Jorge Cortes, 374404

Next-generation cytogenomics in leukemia: opportunities for diagnosis and discovery

ESH eLearning, Steve Eacker, 374399

Introduction

ESH eLearning, Tim Hughes, 374403

Discussion

ESH eLearning, Faculty / Presenters, 374397

Intrinsic

ESH eLearning, Mirle Schemionek-Reinders, 374396

Extrinsic

ESH eLearning, Daniela Krause, 374395

Introduction

ESH eLearning, Ravi Bhatia, 374394

Selected abstract: Long-term treatment outcome and health-related qualityof life of patients with CML treated with TKIs: a single-center report

ESH eLearning, Hee Jeong Cho, 374393

Selected abstract:TFR after nilotinib or dasatinib 1st-line in chronic phase CML patients: characteristics and outcomes

ESH eLearning, Franck Emmanuel Nicolini, 374391

Selected abstract:Final result of TKI discontinuation trial with dasatinib for 2nd attempt of TFR after failing 1st attempt with imatinib: TFR accomplished by dasatinib (TRAD) trial

ESH eLearning, Dennis Kim, 374390

Keynote Presentation:TFR and Pro: Where do we stand? Where to go?

ESH eLearning, Susanne Saussele, 374389

Teamwork

ESH eLearning, Andreas Hochhaus, 374388

Selected abstract:Dose modification dynamics of ponatinib in patients with chronic-phase CML from the PACE and optic trials

ESH eLearning, Gianantonio Rosti, 374387

Selected abstract:Vodobatinib in chronic phase Ph+ CML - updated efficacy results

ESH eLearning, Jorge Cortes, 374386

Selected abstract: Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib vs bosutinib in patients with CML in chronic phase after ≥2 prior tyrosine kinase inhibitors: week 96 update

ESH eLearning, Andreas Hochhaus, 374384

Keynote Presentation:New drugs in CML: which, where and how

ESH eLearning, Valentin Garcia Gutiérrez, 374383

Cancer evolution ecosystems

ESH eLearning, Carlo Maley, 374382

Selected abstract: Deciphering the cooperative mechanism between asciminib and orthosteric inhibitors in stabilizing the inactive conformation of BCR-ABL1 compound mutants

ESH eLearning, Milad ROUHIMOGHADAM, 374379

Selected abstract: Identification of key microRNAs as predictive biomarkers of nilotinib response in CML: a sub-analysis of the ENESTxtnd clinical trial

ESH eLearning, Andrew Wu, 374378

Selected abstract: Relationship between telomere length and clonal hematopoiesis of indeterminate potential in patients with CML at 1st diagnosis and during follow-up under TKI therapy

ESH eLearning, Anna D. Doleschall, 374377

Targeted protein degradation as a tool to probe non-kinase roles in CML

ESH eLearning, George Burslem, 374372

Validation of PROTACs as chemical tools and expanding the tool box of new E3 ligands

ESH eLearning, Stefan Knapp, 374371

General discussion

ESH eLearning, Faculty / Presenters, 374369

The LAST trial: the value of PRO after treatment discontinuation

ESH eLearning, Ehab Atallah, 374368

Lessons learnt from EURO-Ski: where now

ESH eLearning, François-Xavier Mahon, 374367

iCMLf Genomic Alliance – Goals and accomplishments through a global collaboration

ESH eLearning, Susan Branford, 374366

Current understanding mutation assessment and significance in CML

ESH eLearning, Simona SOVERINI, 374365

Champion in CML cooperative research

ESH eLearning, Rüdiger Hehlmann, 374363

Introductory overview – concepts and challenges

ESH eLearning, Giuseppe Saglio, 374362

Selected abstract: Targeting a highly deregulated eIF4F translation initiation complex sensitizes IM-resistant cells to TKI and effectively suppresses BCR-ABL protein expression

ESH eLearning, Ryan Yen, 374361

Selected abstract:Lomerizine blocks calcium ion influx to mitochondria and targets CML stem cells through inhibition of mitochondrial metabolism

ESH eLearning, Ahmed Khalaf, 374358

Combined targeting of CML cells using tyrosine kinase and bone morphogenic protein inhibitors

ESH eLearning, Kudzai Nyamondo, 374356

Restoration of Mir-185 in combination with BCR-ABL downregulation by therapeutic delivery of siRNA with polymeric carriers sensitizes drug resistant cells to TKIs

ESH eLearning, Athena Phoa, 374355

The rate of cellular energy production of muscle cells attenuated by carnitine intracellular deficiency was proved in vivo

ESH eLearning, Pavel Burda, 374354

Synthetic lethality in CML - targeting metabolism effectively complements TKI treatment

ESH eLearning, Lukas Häselbarth, 374353

Immunology aspects of cancer

ESH eLearning, Toni Ribas, 374352

Molecular mechanisms of BCR-ABL regulation and its inhibition by allosteric and orthosteric inhibitors

ESH eLearning, Oliver Hantschel, 374351

Selected abstract:Modeling progression of CML using mutagenized patient-derived induced pluripotent stem cells (IPSCs)

ESH eLearning, Jusuf Imeri, 374350

Selected abstract:BCR-ABL1 -dependent promotion of hematopoietic stem cells (HSC) and progenitors in an inducible embryonic stem cell (ESC) model

ESH eLearning, Jerome Artus, 374348

Selected abstract: Single-cell multiomics reveals the stem and immune composition of stage progression in CML

ESH eLearning, Ya-Ching Hsieh, 374347

BCR::ABL1 Digital PCR identifies chronic phase CML patients suitable for an early TKI discontinuation attempt: a patient-level meta-analysis

ESH eLearning, Camille C.B. Kockerols, 374344

Glucose anaplerosis Is a BCR-ABL Independent Metabolic Vulnerability in CML

ESH eLearning, Kevin Rattigan, 374343

Asciminib provides durable molecular responses in patients with CML in chronic phase (CML-CP) with the T315I mutation: updated efficacy and safety data from a phase I trial

ESH eLearning, Fabian Lang, 374342

A shared molecular mechanism among blastic transformation, residual disease, and primary TKI resistance in CML - MS4A3 suppression

ESH eLearning, Helong Zhao, 374339

Welcome address

ESH eLearning, Jorge Cortes, 374338

Conference Book (PDF)

ESH eLearning, Faculty / Presenters, 374438

Panel Discussion

ESH eLearning, Faculty / Presenters, 373855

Waldenstrom Macroglobulinemia

ESH eLearning, Prashant Kapoor, 373854

AL Amyloidosis

ESH eLearning, Vaishali Sanchorawala, 373853

MGUS

ESH eLearning, Vincent Rajkumar, 373852

Panel Discussion

ESH eLearning, Faculty / Presenters, 373851

Endpoints for frontline therapy

ESH eLearning, Shaji Kumar, 373850

Strategic questions for investigator initated trials

ESH eLearning, Philippe Moreau, 373849

Control arms in regulatory trials

ESH eLearning, Graham Jackson, 373848

Discussion

ESH eLearning, Faculty / Presenters, 373847

Fiction

ESH eLearning, Mohamad Mohty, 373846

Reality

ESH eLearning, Adrian Mosquera, 373845

Where, when and how to use bi-specifics mAbs in MM?

ESH eLearning, Nizar J Bahlis, 373844

Where, when and how to use CAR- cells in MM?

ESH eLearning, Salomon Manier, 373843

Where, when and how to use ADC in MM?

ESH eLearning, Rakesh Popat, 373842